Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.435 USD | +14.71% | +19.91% | -26.92% |
05:15pm | JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating | MT |
May. 10 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 234
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 20-06-30 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | Jan. 16 |
Chief Operating Officer | 52 | 22-08-31 | |
Jeremy Duffield
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-12-31 |
Ann Lee
CTO | Chief Tech/Sci/R&D Officer | 62 | 21-09-30 |
Mohammed Asmal
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fubao Wang
LAW | General Counsel | - | - |
Karen Brown
LAW | General Counsel | - | - |
Niamh Alix
HRO | Human Resources Officer | - | 22-05-31 |
Carman Alenson
AUD | Comptroller/Controller/Auditor | 58 | 21-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 21-11-30 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 20-08-31 |
Michael Kelly
BRD | Director/Board Member | 67 | 21-10-31 |
David Schenkein
BRD | Director/Board Member | 66 | 19-09-12 |
Chief Executive Officer | 70 | 20-06-30 | |
Director/Board Member | 46 | 23-05-09 | |
Thomas Cahill
BRD | Director/Board Member | 37 | 21-10-31 |
Wendy Chung
BRD | Director/Board Member | 55 | 21-10-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 120,028,813 | 90,021,563 ( 75.00 %) | 0 | 75.00 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.92% | 649M | |
+5.77% | 109B | |
+11.29% | 105B | |
-0.38% | 22.25B | |
-12.25% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.37% | 16.85B | |
+3.29% | 13.76B | |
+36.73% | 12.46B |
- Stock Market
- Equities
- PRME Stock
- Company Prime Medicine, Inc.